Neuralstem, Inc. is focused on developing and commercializing of treatments for central nervous system disease based on transplanting human neural stem cells and small molecule drugs. The Company has developed and maintain a portfolio of patents and patent applications that form the base of its research and development efforts in the areas of neural stem cell research, small molecule research, and related technologies.
04/10/11Neuralstem shares jump over 13% on new stem cell patent
16/12/10Neuralstem Receives FDA Approval to Start Phase Ia Trial for Depression Drug
14/09/10Study Shows Neuralstem’s Stem Cells May Have Application To Treating Stroke
Recent Sector News
U.S. stocks halted the five-day losing streak today, as investors looked past softer economic reports and a continued rout in China’s stock market, and waited for the outcome of the two-day Federal Reserve. The S&P 500 (INDEXSP:.INX) rose 1.3 percent to 2,093.59 at 3.45 p.m. in New York. The 30-company Dow Jones Industrial Average (INDEXDJX:.DJI) added 1.1 percent to 17,631.10, while the tech-heavy Nasdaq Composite (INDEXNASDAQ:.IXIC) added 1 percent to 5,088.11.
Teva Pharmaceutical Industries (NYSE:TEVA), an Israeli drugmaker, agreed to buy Dublin-based Allergan PLC's (NYSE:AGN) generic pharmaceuticals business for $40.5 billion in cash and stock, and dropped its hostile offer for Mylan (NASDAQ:MYL). Teva will pay $33.75 billion in cash and $6.75 billion worth of shares at today’s price, or about 10 percent of the enlarged company, the Petach Tikva, Israel-based company said in a statement today.
Approval from the EMA opens the door for a similarly favorable opinion from the World Health Organization (WHO), which could then decide whether to recommend vaccination in countries where malaria is endemic
A month ago, the drug company closed enrollment in clinical tests of its TKM-Ebola in Sierra Leone, after a report concluded that the drug had no beneficial effects.
Pharma companies have sought to expand research and manufacturing facilities in emerging markets to reduce costs. Egypt, despite its political challenges, has seen some of the highest pharmaceutical sales among emerging markets in recent years
Valeant continues to expand in contact lens sector while its share price reaches a record in Toronto
Just last week, Valeant signed a licensing deal for EyeGate Pharmaceuticals, to advance the development of a corticosteroid treatment for uveitis, an inflammatory condition that can lead to lost vision or permanent blindness.
Investors interested in Neuralstem recently viewed
- Epistem Holdings Plc (AIM: EHP) Biotechnology company applying its expertise in epithelial stem cells
- Anteo Diagnostics (ASX: ADO) .
- Medgenics (AMEX , AIM: MDGN) Developing "Biopump" technology for the treatment of chronic diseases
- Imugene Limited (ASX: IMU) .
- Silence Therapeutics (AIM: SLN) A leader in RNAi therapeutics